Amgen (AMGN) Stock
Large biotech company with established medicines and steady dividends. Here's the price, business snapshot, and what's worth knowing about Amgen in August 2026.
Amgen Inc (AMGN) is a large-cap biotechnology company specialising in human therapeutics, particularly biologic medicines. With a market capitalisation around $162 billion, Amgen generates revenue from established products across oncology, nephrology, inflammation and cardiovascular care, while investing heavily in a diverse R&D pipeline of biologics and novel therapies. The company benefits from recurring revenue from long-tenured biologics, a history of steady free cash flow and a shareholder-friendly dividend policy, but faces typical sector risks: clinical trial setbacks, biosimilar competition, pricing pressure and regulatory scrutiny. Investors should watch product patent expiries, pipeline readouts and any M&A activity. This summary is for educational purposes only and not personalised investment advice; suitability depends on an investor’s goals, timeframe and risk tolerance, and returns are not guaranteed.
Why It’s Moving
AMGN is under pressure as investors weigh whether its obesity-drug catalyst is already priced in.
- Analysts flagged MariTide as the key swing factor, saying the obesity-drug program already has meaningful expectations built in, which limits room for a big re-rating unless the upcoming data is clearly stronger than the market expects.
- A recent analyst downgrade to Hold reflects a more cautious stance on near-term upside, with investors now focused on whether pipeline progress can justify the stock’s current valuation.
- The share move is also being shaped by broader biotech sentiment, where heavy competition in obesity drugs and ongoing pricing/regulatory concerns are making investors less willing to pay up for late-stage pipeline stories.
AMGN is under pressure as investors weigh whether its obesity-drug catalyst is already priced in.
- Analysts flagged MariTide as the key swing factor, saying the obesity-drug program already has meaningful expectations built in, which limits room for a big re-rating unless the upcoming data is clearly stronger than the market expects.
- A recent analyst downgrade to Hold reflects a more cautious stance on near-term upside, with investors now focused on whether pipeline progress can justify the stock’s current valuation.
- The share move is also being shaped by broader biotech sentiment, where heavy competition in obesity drugs and ongoing pricing/regulatory concerns are making investors less willing to pay up for late-stage pipeline stories.
When is the next earnings date for AMGEN INC (AMGN)?
The next earnings date for Amgen (AMGN) is August 4, 2026, based on the company’s announced Q2 2026 earnings schedule. The report will cover second-quarter 2026 financial results. Some calendars still show a broader estimated window around early August, but the confirmed date is August 4, 2026.
Stock Performance Snapshot
Analyst Rating
Analysts suggest keeping Amgen's stock as is, with a target price lower than the current price.
Financial Health
Amgen is performing well with strong profits and cash flow, indicating solid financial stability.
Dividend
Amgen's dividend yield of 2.49% indicates a reasonable return for dividend-seeking investors. If you invested $1000 you would be paid $24.90 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
BRIDGEBIO PHARMA INC
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
Baskets Featuring AMGN
TYK2 Inhibitors: Might Oral Drugs Rule Autoimmune?
Alumis's breakthrough trial results for its oral psoriasis drug have highlighted the massive potential of advanced autoimmune therapies. This theme focuses on the pharmaceutical companies pioneering next-generation oral treatments, particularly selective TYK2 inhibitors, which represent a new frontier in convenient and effective patient care.
Published: 7 January 2026
Explore BasketDrug Pricing Power | Major Pharma Stocks 2025
Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.
Published: 2 January 2026
Explore BasketPharma Reshoring Explained | Manufacturing Investment
Major pharmaceutical firms have signed agreements with the U.S. government to lower drug prices in exchange for tariff exemptions and other concessions. This move is expected to drive over $150 billion in new domestic R&D and manufacturing investments, creating opportunities for U.S.-based life sciences and industrial supply chain companies.
Published: 21 December 2025
Explore BasketCancer Therapies: What's Next After 100% Response Rate
Regeneron's announcement of a 100% response rate for its new lymphoma therapy highlights a major advancement in cancer treatment. This breakthrough creates an investment opportunity centered on companies pioneering next-generation immuno-oncology drugs, particularly those developing bispecific antibodies and other innovative platforms.
Published: 7 December 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: 15 July 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: 3 July 2025
Explore BasketProfit Sharers
These established market leaders don't just generate impressive profits—they're committed to sharing that wealth with you. Carefully selected by our analysts, these dividend powerhouses offer both reliable income streams and the stability of industry-leading businesses.
Published: 17 June 2025
Explore BasketTop Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Published: 29 May 2025
Explore BasketWhy You’ll Want to Watch This Stock
Established Biologics Revenue
Amgen’s marketed biologics provide recurring sales and predictable cash flow, though revenue can be affected by patent loss and biosimilar entrants.
Pipeline & R&D Focus
A deep R&D pipeline drives long-term potential; positive trial results can re-rate the business, while failures can materially affect value.
Global Market Exposure
Amgen sells worldwide, benefiting from geographic diversification, but faces regional pricing and regulatory differences that can influence performance.
Compare Amgen with other stocks
Amgen vs Gilead Sciences
Amgen vs Gilead Sciences: Stock Comparison
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
